SIGi001-A-1

Depositor
Sigma-Aldrich

Derivation
Primary cell type: Epithelium
Reprogramming method
Vector type: Integrating
Vector: Virus
Virus type: Retrovirus
Gene list:
KLF4
MYC
POU5F1
SOX2
Have the reprogramming vectors been silenced: Unknown

Characterization
Analysis of Undifferentiated Cells
Marker expression: SSEA-1(-)SSEA-4 (+)POU5F1 (OCT-4) (+)TRA 1-60 (+)
Differentiation potency
Ectoderm: In vitro spontaneous differentiation
Marker Expressed:PAX6 (+)
Endoderm: In vitro spontaneous differentiation
Marker Expressed:GATA6 (+)
Mesoderm: In vitro spontaneous differentiation
Marker Expressed:AFP (+)

Microbiology / Virus Screening
HIV 1: Negative
HIV 2: Negative
Hepatitis B: Negative
Hepatitis C: Negative
Mycoplasma: Negative
Sterility
Inoculation for microbiological growth: No Contaminants Detected
Mycoplasma: Not Detected
Viability: Viable post-cryopreservation

Genotyping
Karyotyping
Passage number: 37
Cell line karyotype: No autosomal or sex chromosome abnormalities detected
Karyotyping method: Karyolite BoBs
Genotyping
STR/Fingerprinting: A 16 allele profile has been recorded and data is available upon request, after cell line purchase.

Genetic Modification
Disease/phenotype related modifications
Disease: Corticobasal degeneration
There are three disease associations for the edited subclone: PSP (progressive supranuclear palsy) /CBD (Corticobasal degeneration) / FTDP-17 (Frontotemporal dementia and parkinsonism linked to chromosome 17) - like symptoms
Type of modification: Isogenic
Gene: MAPT
Chromosome location: 17q21.31
Zygosity: Homozygous
Target locus modification: Mutated
Description: P301S+IVS10+16 C>T
Disease: Progressive supranuclear palsy
There are three disease associations for the edited subclone: PSP (progressive supranuclear palsy) /CBD (Corticobasal degeneration) / FTDP-17 (Frontotemporal dementia and parkinsonism linked to chromosome 17) - like symptoms

Induced pluripotent stem cells (iPSCs) are adult cells that have been reprogrammed to an embryonic stem cell–like state. The cells can replicate indefinitely or, under controlled conditions, can be differentiated into any other cell type such as nerve, heart or liver cells. Medical researchers are able to use iPS cells to test how different patients might respond to new drugs or to analyse how genetic diseases develop.

The EBiSC stem cell bank is a collection of human iPS cells available to academic and commercial researchers for use in disease modelling and other forms of stem cell research. The initial collection has been generated from a wide range of donors representing specific disease backgrounds and healthy controls. EBiSC has established many routine procedures for collecting, expanding and characterizing human iPS cell lines. The stem cell bank includes iPSC cell lines derived from neurodegenerative diseases (Alzheimer′s Disease, Parkinson′s Disease, Dementia, Motor Neuron Disease (ALS) - and Huntington′s Disease), eye and heart diseases, and lines from healthy control donors for age and sex matching.

Note: EAUA and CLIP must be completed before order fulfillment

Medium: mTeSR^®
Passage method: EDTA
Matrix: Matrigel^® / Geltrex^®
CO₂ concentration: 5%
O₂ concentration: 21%
Temperature: 37°C

EBiSC is a trademark of Fraunhofer-Gesellschaft

GELTREX is a registered trademark of Life Technologies Corporation

Matrigel is a registered trademark of Corning, Inc.

mTeSR is a registered trademark of WiCell Research Institute, Inc.